3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis

Richard B Warren; Kristian Reich; Eric L Simpson; Richard Langley; Antonio Costanzo; Hidehisa Saeki; Peter Almgren; Emilia Vacko; Melinda Gooderham; Mette Deleuran; Juan Francisco Silvestre; Stefan Weidinger; Andrew Blauvelt

doi:10.25251/skin.6.supp.78

Richard B Warren

Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester

Kristian Reich

Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf

Eric L Simpson

Oregon Health & Science University

Richard Langley

Dalhousie University

Antonio Costanzo

Dermatology Unit Department of Biomedical Sciences, Humanitas University

Hidehisa Saeki

Department of Dermatology, Nippon Medical Scholo

Peter Almgren

Leo Pharma Inc.

Emilia Vacko

Leo Pharma Inc.

Melinda Gooderham

Skin Centre for Dermatology

Mette Deleuran

Aarhus University Hospital Department of Dermatology

Juan Francisco Silvestre

Hospital General Universitario de Alicante

Stefan Weidinger

University Hospital Schleswig-Holstein, Campus Kiel

Andrew Blauvelt

Oregon Medical Research Center

Keywords

tralokinumab, atopic dermatitis, efficacy

References

1. Weidinger S, Novak N. Lancet. 2016;387(10023):1109-1122

2. Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2022;36(9):1409-1431

3. de Bruin-Weller M, et al. Acta Derm Venereol 2021; 101: adv00402

4. Blauvelt A, et al. Poster presented at: American Academy of Dermatology Annual Meeting; March 25-29, 2022, Boston, MA

5. Blauvelt A, et al. J Am Acad Dermatol. 2022;S0190-9622(22)02345-3

6. Simpson E, et al. Poster presented at: Revolutionizing Atopic Dermatitis (RAD) Conference; December 13–14, 2020, Virtual

7. Chuang-Stein C. Pharm Stat 2011; 10:3–7

Poster PDF

Published

Nov 16, 2022

DOI https://doi.org/10.25251/skin.6.supp.78

How to Cite

[1]

Warren, R.B., Reich, K., Simpson, E.L., Langley, R., Costanzo, A., Saeki, H., Almgren, P., Vacko, E., Gooderham, M., Deleuran, M., Francisco Silvestre, J., Weidinger, S. and Blauvelt, A. 2022. 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s78. DOI:https://doi.org/10.25251/skin.6.supp.78.

Issue

Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson, Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Diamant Thaci, Kenneth Gordon , Melinda Gooderham, Bruce Strober , Neil Korman, Subhashis Banerjee, Subhashis Banerjee, Elizabeth Colston, Jonghyeon Kim, John Throup, Akimichi Morita, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan, Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, Mark Lebwohl, David Adam, Javier Alonso-Llamazares, Chih-ho Hong, Steve Kempers, Leon Kircik, Wei Jing Loo, Daniel Stewart, Walter Nahm, Matthew Zirwas, Patrick Burnett, Robert Higham, Lynn Navale, David Berk, Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Andrew Blauvelt, Steven Kempers, Seth Forman, Edward Lain, Suzanne Bruce, Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Linda Stein Gold, Mark Lebwohl, Kim Papp, Melinda Gooderham, Leon Kircik, Zoe Draelos, Steven Kempers, David Pariser, Javier Alonso-Llamazares, Darryl Toth, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Jerry Bagel, John Nia, Peter Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Elsa Muscianisi, Andrew Blauvelt, Mark Lebwohl, Secukinumab is Superior to Ustekinumab in Clearing Skin of Patients with Moderate to Severe Plaque Psoriasis: CLARITY, a Randomized, Controlled, Phase 3b Trial , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Leon Kircik, Mark Lebwohl, Kim Papp, Melinda Gooderham, Linda Stein Gold, Zoe Draelos, Steven Kempers, Stephen Tyring, Lorne Albrecht, Marni Wiseman, Laura Ferris, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk, Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

References

Article Sidebar

Article Details

Most read articles by the same author(s)